Key Insights

Highlights

Success Rate

86% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

7.7%

1 terminated out of 13 trials

Success Rate

85.7%

-0.8% vs benchmark

Late-Stage Pipeline

8%

1 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed with results

Key Signals

3 with results86% success

Data Visualizations

Phase Distribution

9Total
Not Applicable (4)
P 1 (2)
P 2 (2)
P 4 (1)

Trial Status

Completed6
Recruiting2
Withdrawn1
Enrolling By Invitation1
Terminated1
Unknown1

Trial Success Rate

85.7%

Benchmark: 86.5%

Based on 6 completed trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT07011147Not ApplicableRecruiting

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT06405373Not ApplicableRecruiting

Behavioral Approaches to Reduce Diabetes Distress in Adults With Type 1 Diabetes: A Pragmatic SMART

NCT03406897Phase 1Completed

Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients

NCT06786546Enrolling By Invitation

Type 1 Diabetes Autonomic and Vascular Function

NCT06573905Not Yet Recruiting

Mapping Diabetes in Quebec: Validating Medico-administrative Algorithms for Type 1 Diabetes, Type 2 Diabetes and LADA

NCT06405386Not ApplicableCompleted

Pilot of Pragmatic Delivery of Behavioral Approaches to Reduce Diabetes Distress in Adults With Type 1 Diabetes

NCT05168657Not ApplicableCompleted

Feasibility of Closed-loop Automated Insulin Delivery System by Primary Care & Endocrinology, in Person & Via Telehealth

NCT03243058Phase 1Withdrawn

Low-dose IL-2 in Established T1D - The "PROREG" Study

NCT04074668Completed

Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance

NCT03878277Phase 2Completed

Evaluation of Coffee Therapy for Improvement of Renal Oxygenation

NCT05013346Unknown

Characteristics of Young-onset Diabetes in Sub-Saharan Africa (YODA) Study

NCT01109927Phase 4CompletedPrimary

Early Insulin Treatment in Patients With Latent Autoimmune Diabetes

NCT00058981Phase 2TerminatedPrimary

Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)

Showing all 13 trials

Research Network

Activity Timeline